Toft Group Completes Executive Search for CareDx (NASDAQ: CDNA) in Brisbane, CA

caredx

Executive search firm Toft Group has placed Mr. Jeffrey Salzman as Head of Reimbursement & Billing at CareDx (NASDAQ: CDNA) in Brisbane, CA. Bringing more than 20 years of experience in the healthcare industry, Mr. Salzman most recently served as Sr. Director of Reimbursement & Health Policy at Transplant Genomics, Inc. in Brookline, MA. Mr. Salzman holds a Bachelor’s degree in Marketing from Florida State University College of Business in Tallahassee, FL, and a Master of Health Management from St. Thomas University in Miami, FL.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The Company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP®, a set of HLA typing is used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation; and XM-ONE®, the first standardized test that quickly identifies a patient's antigens against HLA Class I, Class II or antibodies against a donor's endothelium.